Mability

Consulting with a strategic focus using immunohistochemistry for biopharma clinical trials Providing a comprehensive and detailed overview of the immunohistochemistry field and understand current and prospective trends of that market. Using available time to help others make informed decisions when it comes to investing in this technology or expanding their business operations into the spatial biology market, as well as develop strategies to stay competitive Offering guidance for monoplex and multiplex immunohistochemistry and immunofluorescence, with recommendations for value-add spatial biology technology to expedite clinical decision making Biopharma needs robust platforms to move quickly from discovery to diagnostics. There is a growing need to identify complex phenotypes or provide spatial relationships, particularly in immuno-oncology. Multiplex immunohistochemistry with spatial readouts can identify clinically relevant marker sets for early stage trials and facilitate better designs for the late stage Gap analysis, advising clients how to turn discovery-driven findings into standardized, reproducible and high throughput clinical assays. Design of technical studies and strategy with probability of success for diagnostics and commercialization Connecting biopharma teams with contract research service organizations and alignment of operating models. Helping draft project plans, including milestones, risks or obstacles, for key programs